North Dakota State Investment Board Invests $1.31 Million in IQVIA Holdings Inc. $IQV

North Dakota State Investment Board bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,792 shares of the medical research company’s stock, valued at approximately $1,306,000.

Several other large investors have also added to or reduced their stakes in IQV. Boston Partners purchased a new position in shares of IQVIA during the third quarter worth about $676,698,000. AQR Capital Management LLC lifted its position in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. Citigroup Inc. lifted its position in IQVIA by 108.2% in the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after buying an additional 475,557 shares during the last quarter. Cantillon Capital Management LLC lifted its position in IQVIA by 27.3% in the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after buying an additional 413,256 shares during the last quarter. Finally, Invesco Ltd. lifted its position in IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after buying an additional 367,204 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IQV shares. Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. BMO Capital Markets set a $250.00 target price on IQVIA in a research note on Friday, February 6th. Morgan Stanley set a $225.00 price target on IQVIA in a research report on Thursday, May 7th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $225.69.

IQVIA Trading Up 0.2%

Shares of NYSE:IQV opened at $173.10 on Wednesday. The company has a market cap of $28.89 billion, a P/E ratio of 21.45, a PEG ratio of 1.65 and a beta of 1.18. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock’s fifty day moving average price is $170.00 and its 200-day moving average price is $198.42.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.